Written by Ralph Sun
Biogen Inc. (BIIB) stands at a pivotal juncture in 2026. The neuroscience giant is aggressively pivoting from its legacy multiple sclerosis franchise toward new growth vectors in Alzheimer’s disease, rare diseases, and nephrology. Following a series of high-profile acquisitions and pipeline updates, the company’s first-quarter 2026 results reveal a transitional phase marked by resilient profitability but top-line pressure. As the company integrates its recent $5.6 billion acquisition of Apellis Pharmaceuticals, investors must weigh the near-term execution risks against the long-term compounding potential of its diversified portfolio.
Financial Performance and Core Metrics
In the first quarter of 2026, Biogen reported total revenue of $2.48 billion, representing a modest 2% year-over-year increase. Despite the tepid top-line growth, the company demonstrated exceptional earnings leverage. GAAP diluted earnings per share (EPS) surged 31% to $2.15, while Non-GAAP diluted EPS rose 18% to $3.57. This profitability expansion was driven by a disciplined cost structure and the accelerating contribution of its growth products, which collectively grew 12% year-over-year.
The company generated $594.3 million in free cash flow during the quarter and ended March with a robust $3.38 billion in cash and cash equivalents. However, the full-year 2026 guidance reflects the ongoing erosion of its legacy multiple sclerosis portfolio. Management anticipates a mid-single-digit percentage decline in total revenue compared to 2025, with Non-GAAP diluted EPS projected between $14.25 and $15.25, excluding the impact of the Apellis acquisition.
| Metric | Q1 2026 Results | Year-over-Year Change |
| Total Revenue | $2.48 Billion | +2% |
| GAAP Diluted EPS | $2.15 | +31% |
| Non-GAAP Diluted EPS | $3.57 | +18% |
| Growth Products Revenue | Collective | +12% |
| Free Cash Flow | $594.3 Million | N/A |
The Alzheimer’s Arena: Leqembi vs. Kisunla
The Alzheimer’s disease market remains a central pillar of Biogen’s growth narrative. Leqembi, partnered with Eisai, generated $168 million in in-market sales during Q1 2026, representing a robust 74% year-over-year growth trajectory. The drug’s momentum is supported by strong real-world persistence data and the recent FDA approval of subcutaneous maintenance dosing via LEQEMBI IQLIK.
However, the competitive landscape is intensifying. Eli Lilly’s Kisunla (donanemab) posted strong first-quarter growth with $124 million in revenue. The rivalry between Leqembi and Kisunla is reshaping physician preferences and formulary dynamics. While Biogen and Eisai enjoy a first-mover advantage, Eli Lilly’s formidable commercial muscle and broader metabolic portfolio provide a significant competitive edge.
Biogen is also advancing its next-generation Alzheimer’s pipeline. The Phase 2 CELIA study evaluating diranersen, a tau-targeting antisense oligonucleotide partnered with Ionis Pharmaceuticals, yielded what H.C. Wainwright described as “historic” topline results regarding tau pathology reduction. Despite missing the primary endpoint, Biogen is advancing the asset into Phase 3 trials, underscoring its commitment to multi-modal Alzheimer’s treatments.
Strategic Acquisitions and Pipeline Reshaping
The $5.6 billion acquisition of Apellis Pharmaceuticals, completed in May 2026, represents a bold strategic pivot. The deal brings two commercialized assets: EMPAVELI for rare kidney diseases (C3 glomerulopathy and primary IC-MPGN) and SYFOVRE for geographic atrophy secondary to age-related macular degeneration. Together, these products generated $689 million in 2025 revenue. Biogen expects the acquisition to be accretive to Non-GAAP EPS by 2027 and to materially increase its EPS compound annual growth rate through the end of the decade.
This acquisition synergizes with Biogen’s recent agreement with TJ Biopharma for exclusive Greater China rights to felzartamab, establishing a formidable nephrology franchise. The combination of Apellis’s established nephrology commercial infrastructure with felzartamab’s Phase 3 readout anticipated in the first half of 2027 creates a compelling growth vector.
Conversely, Biogen is aggressively pruning underperforming assets. The company recently discontinued the development of BIIB122, a Parkinson’s disease drug partnered with Denali Therapeutics, after it failed to meet the primary endpoint in the Phase 2b LUMA study. Meanwhile, positive Phase 3 results for dapirolizumab pegol in systemic lupus erythematosus, partnered with UCB, published in The Lancet, offer a potential new revenue stream in autoimmune disease.
Growth Products Portfolio
Beyond Alzheimer’s, Biogen’s growth products portfolio demonstrates broad-based momentum. SKYCLARYS, the company’s treatment for Friedreich’s Ataxia, generated $151 million in Q1 2026 revenue. ZURZUVAE, for postpartum depression, contributed $55 million. QALSODY, targeting amyotrophic lateral sclerosis, added $33 million. SPINRAZA, while mature, remains a $374 million quarterly contributor, bolstered by the recent U.S. approval of the High Dose Regimen.
The anti-CD20 programs generated $419.1 million in Q1 2026 revenue, providing a stable royalty stream. VUMERITY, Biogen’s next-generation oral MS therapy, contributed $179 million. While the legacy MS franchise faces generic erosion, the diversification into rare diseases and neurology adjacencies is progressing on schedule.
Equities Orbis Stock Ratings and Price Targets
Based on our comprehensive analysis of the neuroscience sector and current market dynamics, Equities Orbis issues the following ratings and twelve-month price targets.
| Company (Ticker) | Rating | Price Target | Rationale |
| Biogen Inc. (BIIB) | HOLD | $220.00 | Strategic pivot sound but near-term revenue decline limits upside; Apellis integration risk. |
| Eli Lilly (LLY) | BUY | $1,200.00 | Explosive incretin growth and Kisunla launch; dominant commercial execution. |
| Regeneron (REGN) | BUY | $825.00 | Robust immunology/ophthalmology portfolio; deep pipeline and strong cash generation. |
| Eisai Co., Ltd. (ESALY) | BUY | $22.00 | Primary Leqembi beneficiary; doubling sales trajectory and subcutaneous dosing catalyst. |
| Denali Therapeutics (DNLI) | SELL | $20.00 | LUMA study failure removes key catalyst; elevated risk profile. |
| Ionis Pharmaceuticals (IONS) | HOLD | $85.00 | Diversified ASO platform but mixed CELIA results highlight neurological development risk. |
| Roche Holding AG (RHHBY) | HOLD | $40.00 | Robust pipeline but lacks immediate transformative growth drivers vs. peers. |
Biogen Inc. (BIIB) – HOLD – Price Target: $220.00
Biogen is successfully executing its strategic pivot, but the near-term revenue contraction from its legacy multiple sclerosis franchise limits immediate upside. The Apellis acquisition provides a clear path to EPS growth by 2027, but integration risks and intense competition in the Alzheimer’s space warrant a cautious approach. At a forward P/E of approximately 14.5x, the stock is not expensive, but we recommend holding until the revenue inflection from Leqembi and the newly acquired Apellis assets materializes in the second half of 2026 and into 2027.
Eli Lilly and Company (LLY) – BUY – Price Target: $1,200.00
Eli Lilly remains a dominant force in biopharma, driven by the explosive growth of its incretin franchise (Mounjaro/Zepbound) and the accelerating launch of Kisunla in Alzheimer’s disease. The company’s Q1 2026 revenue surged 55.5% year-over-year to $19.80 billion, with Mounjaro alone generating $8.66 billion. The sheer magnitude of its metabolic and neuroscience portfolios justifies a premium valuation. Kisunla’s competitive positioning against Leqembi adds another growth vector that the market has not fully priced in.
Regeneron Pharmaceuticals, Inc. (REGN) – BUY – Price Target: $825.00
Regeneron continues to demonstrate robust execution across its core immunology and ophthalmology portfolios. With Dupixent generating blockbuster revenues and a deep pipeline spanning oncology, cardiovascular, and rare diseases, the company offers a compelling risk-reward profile. The current price near $615 represents significant upside to our $825 target, supported by strong free cash flow generation and a proven R&D engine.
Eisai Co., Ltd. (ESALY) – BUY – Price Target: $22.00
As the lead partner on Leqembi, Eisai is the primary beneficiary of the drug’s commercial acceleration. The doubling of Leqembi sales in FY2025 and the rollout of subcutaneous dosing provide a clear runway for sustained top-line growth. Eisai’s focused neuroscience strategy and the global expansion of Leqembi into additional markets support a constructive outlook.
Denali Therapeutics Inc. (DNLI) – SELL – Price Target: $20.00
The failure of the Phase 2b LUMA study for BIIB122 removes a significant near-term catalyst for Denali. While the company maintains a broad blood-brain barrier transport technology platform, the clinical setback in Parkinson’s disease significantly increases the risk profile. The stock trades near $19-20, and without a clear near-term value driver, we see limited upside and recommend selling.
Ionis Pharmaceuticals, Inc. (IONS) – HOLD – Price Target: $85.00
Ionis offers a diversified antisense oligonucleotide platform with multiple partnered programs. However, the mixed results from the CELIA study with Biogen highlight the inherent risks in neurological drug development. While the tau reduction data is promising, the failure to meet the primary endpoint suggests a protracted and uncertain path to commercialization for diranersen. We recommend holding while awaiting Phase 3 design clarity.
Roche Holding AG (RHHBY) – HOLD – Price Target: $40.00
Roche maintains a formidable presence in neuroscience and oncology, with mid-single-digit sales growth expected in 2026. However, recent earnings have failed to catalyze significant stock movement. The company’s pipeline is robust, including a MAGL inhibitor for CNS inflammation, but it lacks the immediate, transformative growth drivers seen in peers like Eli Lilly. We maintain a neutral stance pending clearer catalysts.
Conclusion
Biogen is navigating a complex transition, trading legacy cash flows for future growth in highly competitive therapeutic areas. The strategic rationale for the Apellis acquisition and the continued investment in Alzheimer’s disease are sound, but the execution window is tight. The company’s forward P/E of 14.5x reflects the market’s skepticism about near-term growth, creating potential upside if management delivers on its 2027 accretion targets. Investors should maintain a neutral stance on Biogen while favoring companies with clearer, unencumbered growth trajectories like Eli Lilly and Regeneron.
— Equities Orbis —
Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Investors should conduct their own due diligence before making investment decisions.
